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Abstract
We examined the association between C-reactive protein (CRP) level at time of blood culture (BC) draw and mortality following bac-
teraemia. Our population-based cohort study comprised all ﬁrst-time monomicrobial bacteraemia episodes in adults in a Danish county
during 1996–2004 (n = 5267). CRP was measured within 24 h of the ﬁrst positive BC draw. Cox regression was used to compute
mortality rate ratios (MRRs) associated with CRP level quartiles (10–64 (reference), 65–143, 144–240 and 241–688 mg/L), controlling
for age, gender, comorbidity, specialty, acquisition of infection, and infection focus. We also looked for a biological interaction between
CRP level and high magnitude of bacteraemia (three of three culture bottles positive). Thirty-day mortality increased with higher CRP
level: adjusted 0–30-day MRRs for patients in the second, third and fourth CRP quartiles were 1.38 (95% CI 1.13–1.69), 1.70
(95% CI 1.40–2.06), and 2.38 (95% CI 1.96–2.87), respectively (p for trend <10)4). In contrast, mortality associations with CRP during
31–365 days of follow-up were weak (adjusted MRRs for the second to fourth quartiles ranged from 1.18 to 1.28). A high magnitude of
bacteraemia strengthened the association between high CRP level and 30-day mortality. We conclude that the CRP level, measured
concurrently with the ﬁrst positive BC, independently predicted 30-day mortality in adult bacteraemia patients.
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Introduction
C-reactive protein (CRP) is a widely used acute-phase sepsis
marker [1]. A few small clinical studies of hospitalized
patients with infection [2–5] and two larger studies among
pneumonia patients [6,7] showed that the initial CRP level
was associated with increased 30-day mortality. Information
is limited for CRP in other infections, including bacteraemia.
Bacteraemia is diagnosed by blood culture (BC), and the
CRP level is usually determined concomitantly with the ﬁrst
positive BC. We hypothesized that this baseline CRP level is
an independent predictor of short-term and longer-term
mortality in bacteraemia patients. Previously, we reported
that high magnitude of bacteraemia predicts higher 30-day
mortality [8]. In the same population-based cohort, we
examined whether the baseline CRP level predicts mortality
and whether a high magnitude of bacteraemia inﬂuences this
association.
Materials and Methods
Setting and initial study cohort
The initial study cohort (all ﬁrst-time monomicrobial
bactaeremias in adults in North Jutland County, Denmark,
1996–2004) has been previously described [8]. The main
host characteristics were age, gender, comorbidity, and date
of death. We classiﬁed comorbidity using the Charlson
index, which assigns scores to 19 major diseases [9]. The
main bacteraemia characteristics were bacterial species,
specialty, acquisition of infection, infection focus, and the BC
index (number of bacteria-positive BC bottles in the initial
three-bottle BC set).
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Data on CRP
Values were recorded as mg/L, with 10 mg/L being the low-
est recorded value. We linked the initial study cohort to
CRP results, which have been electronically recorded since
1997.
Final study cohort
The initial study cohort from 1997 through 2004 comprised
5730 patients, including 281 with missing CRP measure-
ments. For the 5449 remaining patients, we had the date,
hour and minute for drawing the CRP specimen and the ﬁrst
positive BC set (for one patient, we only had the date for
the BC set). We included the CRP level from the specimen
drawn within the shortest time period to the ﬁrst positive
BC set. After exclusion of 182 patients with >24 h between
the BC set and the CRP specimen, the ﬁnal study cohort
comprised 5267 patients.
Statistical analyses
We examined 0–30-day and 31–365-day mortality. For each
follow-up period, we applied three statistical models to
examine the most efﬁcacious use of CRP levels in the
adjusted Cox proportional hazards regression analysis (see
below) [10–12]. This showed that the use of CRP level quar-
tiles did not compromise the impact of CRP as a continuous
parameter (see Appendix S1).
We used the Kruskal–Wallis test to evaluate CRP level
differences between subgroups. If p <0.05 and there were
more than two subgroups, we used the Mann–Whitney test
to compare subgroups pairwise (a = 0.05).
For the CRP quartiles, we computed mortality rates, both
crude and directly standardized to the age and comorbidity
distribution in the ﬁrst quartile (standardized mortality rates
(SMRs)).
We used Cox regression analysis to estimate mortality
rate ratios (MRRs) with 95% CIs, using the lowest CRP quar-
tile as reference. In addition to the crude analyses, we
adjusted for age, gender, Charlson index, specialty, acquisi-
tion of infection, and infection focus. We repeated the analy-
ses within the major subgroups.
Thereafter, we combined the CRP quartiles with the BC
indices (one and two positive bottles merged, as these pre-
dicted similar mortality [8]) and repeated all analyses, using
the lowest CRP quartile with BC index 1/2 as the reference
group.
For all Cox models, the proportional hazard assumption
was assessed graphically and found to be appropriate. More-
over, we assessed the statistical interaction between the
CRP quartiles and the BC indices, using the likelihood ratio
test.
The program STATA/SE 9.2 (Stata Corporation, College
Station, TX, USA) was used for analyses.
Ethical considerations
The study was approved by the Danish Data Protection
Agency (Record 2006-41-6969).
Results
Descriptive data
The CRP level differed little between age and comorbidity
subgroups (Table 1). CRP levels were lower among BC
index 1 patients, males, liver disease patients, surgical
patients, and patients with healthcare-related, nosocomial or
Gram-negative bacteraemia. Patients with a respiratory focus
or Streptococcus pneumoniae infection had relatively high CRP
levels.
Mortality analyses for CRP quartiles
Thirty-day mortality increased consistently from 13.2% in the
ﬁrst CRP quartile to 24.8% in the fourth CRP quartile
(Table 2). No such trend was seen for 31–365-day mortality.
SMRs were similar to the crude mortality rates.
Adjusted 30-day MRRs for patients in the second, third
and fourth CRP quartiles were 1.38 (95% CI 1.13–1.69), 1.70
(95% CI 1.40–2.06), and 2.38 (95% CI 1.96–2.87), respec-
tively (Table 2). In contrast, the 31–365-day MRRs were
weak, ranging from 1.18 to 1.28. Crude and adjusted MRRs
differed materially only for the fourth CRP quartile, in which
MRRs increased after adjustment.
Mortality analyses for combined CRP quartile and BC index
Thirty-day mortality increased consistently from 11.1% in the
ﬁrst quartile with BC indices 1/2 to 27.6% in the fourth
quartile with BC index 3 (Table 2, Fig. 1a). No such trend
was seen for 31–365-day mortality. SMRs were similar to
the crude mortality rates (Table 2).
There was no statistical interaction between the CRP
quartiles and the dichotomized BC indices (data not
shown).
Within each of the CRP quartiles, adjusted 30-day MRRs
were higher for BC index 3 than for indices 1/2, most mark-
edly in the fourth quartile (Table 2, Fig. 1b).
Survival analyses in major subgroups
Findings in major subgroups (Table 1) were consistent with
the overall ﬁndings, except in patients with a respiratory
focus or S. pneumoniae infection, in whom the CRP level was
unassociated with 30-day mortality (data not shown).
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Discussion
We found that, in adult bacteraemia patients, higher CRP
levels measured concurrently with the ﬁrst positive BC set
strongly predicted increased 30-day mortality.
This is the ﬁrst study enrolling virtually all bacteraemia
patients from a well-deﬁned geographical area to evaluate
CRP as a prognostic predictor. Most previous prognostic
studies involving CRP included <100 patients in one ward,
and focused on speciﬁc infections, such as pneumonia [7,13–
15].
Few studies have evaluated CRP as a continuous parame-
ter, and no study has performed model evaluation. CRP lev-
els were often dichotomized with cut-off levels of 50 or
100 mg/L [6,7,16], which may distinguish between infectious
and non-infectious conditions [1]. This dichotomization is,
however, not pertinent for CRP as a prognostic marker, and
it may lead to loss of valuable information [17]. We found
a linear relationship between the CRP level and 0–30-day
log-mortality (see Appendix S1), which is biologically plausi-
ble, as the CRP level represents the magnitude of the septic
condition.
The use of CRP quartiles resulted in minimal loss of infor-
mation and facilitated combination with our BC index [8].
We could thus quantify these two parameters as fairly inde-
pendent of baseline host and bacteraemia characteristics.
Interestingly, in the 0–30-day period, there was an additive/
biological interaction, as differences between BC indices 1/2
and 3 increased with increasing CRP quartile. Thus, the path-
ogen’s proliferation and the host response seem to be dis-
tinctive prognostic markers in the early inﬂammatory phase.
Curiously, a high CRP level was a stronger predictor in
the adjusted than in the crude model. This was related to
lower CRP levels in some frail patient groups, who also suf-
fered from higher mortality [18,19]. CRP levels are probably
TABLE 1. Distribution of C-reac-
tive protein (CRP) levels
Group
Subgroup
(no. of patients)
CRP level median
(25th, 75th
percentile) (mg/L) KW pa MWb
All patients 144 (65, 241)
Age (years) 16–64 (1763) 146 (62, 249) 0.74
65–80 (2102) 144 (66, 239)
>80 (1402) 143 (66, 232)
Gender Male (2809) 131 (60, 228) 10)4
Female (2458) 156 (73, 257)
Charlson comorbidity
index score
0 (2209) 148 (65, 251) 0.18
1–2 (2034) 145 (66, 238)
>2 (1024) 133 (61, 222)
Liver diseasesc Yes (119) 86 (45, 160) <10)5
No (5148) 145 (65, 243)
BC indexd 1 (1660) 137 (62, 226) 0.03 a
2 (971) 154 (67, 247) b
3 (2636) 145 (66, 250) b
Specialitye Surgical (1375) 134 (60, 226) 0.004 a
Medical (3194) 149 (66, 251) b
ICU (510) 146 (73, 235) b
Acquisition of infectionf Community (2655) 164 (73, 272) 10)4 a
Healthcare (807) 126 (56, 220) b
Nosocomial (1794) 120 (60, 206) b
Infection focus Urinary (1673) 136 (67, 218) 10)4 a
Respiratory (694) 247 (117, 330) b
Abdominal/hepatobiliary (843) 137 (62, 221) a
Otherg (935) 121 (54, 235) a
Unknown (1122) 132 (60, 222) a
Bacterial groupsh Gram-positive (2209) 153 (62, 273) 10)4
Gram-negative (3055) 138 (67, 222)
Bacterial species Staphylococcus aureus (791) 145 (62, 237) 10)4 a
Streptococcus pneumoniae (661) 254 (130, 336) b
Escherichia coli (1855) 140 (71, 222) ac
Enterobacteriaceaei (804) 127 (63, 212) d
Other (1156) 109 (48, 216) e
BC, blood culture; ICU, intensive-care unit; KW, Kruskal–Wallis; MW, Mann–Whitney.
ap-Value in KW test for homogeneity in CRP level distributions within groups.
bMW U-test for CRP level distributions, comparing subgroups pairwise within groups if KW test p <0.05 for the
group and the number of subgroups is >2. Different letters designate differences between subgroups (p <0.05).
cInternational Classiﬁcation of Diseases (ICD)-8 codes 070.00, 070.02, 070.04, 070.06, 070.08, 456.00–456.09, 571,
573.00, 573.01, and 573.04, and ICD-10 codes B15.0, B16.0, B18, B19.0, I85, K70.0–K70.4, K70.9, K71–K74, K76.0,
and K76.6.
dNumber of positive BC bottles (one, two, or three) in a three-bottle BC set.
e‘Miscellaneous’ (mainly mixed surgical/medical wards in smaller hospitals) omitted (n = 188).
f‘Unknown’ (n = 11) omitted.
gMainly the circulatory system, central nervous system, bones, joints, or soft tissues.
hPatients with unknown bacterial species (n = 3) omitted.
iAll Enterobacteriaceae other than E. coli.
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age-independent [20], and we also found this. We are not
aware of studies on CRP levels related to other patient char-
acteristics, apart from hepatic failure.
The association between higher CRP levels on admission
and higher in-hospital mortality has generally been reported
from other studies of infectious conditions, including blood-
TABLE 2. Association between C-reactive protein (CRP) level at time of ﬁrst positive blood culture (BC) and 0–30-day and
31–365-day mortality
Characteristic
0–30 days 31–365 days
Mortality rate MRR (95% CI) Mortality rate MRR (95% CI)
Crude SMRa Crude Adjustedb Crude SMRa Crude Adjustedb
CRP level quartile
1st 13.2 13.2 1 (reference) 1 (reference) 21.8 21.8 1 (reference) 1 (reference)
2nd 18.1 17.8 1.42 (1.16–1.73) 1.38 (1.13–1.69) 27.3 26.4 1.30 (1.09–1.54) 1.28 (1.07–1.52)
3rd 21.1 20.9 1.68 (1.38–2.03) 1.70 (1.40–2.06) 23.5 23.4 1.13 (0.95–1.35) 1.18 (0.98–1.41)
4th 24.8 26.1 2.03 (1.68–2.45) 2.38 (1.96–2.87) 18.8 21.9 0.86 (0.71–1.04) 1.21 (1.00–1.47)
p for trend <10)4 <10)4 <10)4 <10)4 NAc NA NA NA
CRP level quartile/BC indexd
1st/1–2 11.1 11.1 1 (reference) 1 (reference) 22.6 22.6 1 (reference) 1 (reference)
1st/3 15.2 15.2 1.45 (1.06–1.97) 1.46 (1.07–1.99) 20.9 19.9 0.94 (0.73–1.21) 0.89 (0.69–1.16)
2nd/1–2 16.3 15.7 1.61 (1.19–2.17) 1.51 (1.12–2.04) 27.1 25.7 1.28 (1.01–1.63) 1.20 (0.95–1.52)
2nd/3 19.9 19.0 1.84 (1.37–2.47) 1.86 (1.39–2.50) 27.5 26.7 1.23 (0.97–1.56) 1.22 (0.96–1.55)
3rd/1–2 19.3 18.8 1.82 (1.36–2.44) 1.84 (1.37–2.46) 22.5 21.6 1.03 (0.80–1.31) 1.02 (0.80–1.31)
3rd/3 23.2 22.2 2.29 (1.72–3.04) 2.33 (1.75–3.10) 24.7 24.5 1.19 (0.93–1.52) 1.23 (0.96–1.57)
4th/1–2 21.5 22.4 2.07 (1.55–2.77) 2.21 (1.65–2.96) 17.6 19.7 0.78 (0.60–1.02) 1.01 (0.77–1.33)
4th/3 27.6 29.0 2.84 (2.16–3.74) 3.68 (2.79–4.86) 19.9 23.4 0.89 (0.69–1.15) 1.31 (1.01–1.71)
p for trend <10)4 <10)4 <10)4 <10)4 NA NA NA NA
MRR, mortality rate ratio; NA, not applicable; SMR, standardized mortality rate.
aMortality rate, standardized to the age and comorbidity distribution in the reference group.
bAdjusted for age, gender, Charlson comorbidity index, specialty, acquisition of infection, and infection focus (text).
cNA, as p <0.05 in the likelihood ratio test in which quartiles as categorical and continuous parameters were compared.
dBC index: 1–2 = one or two positive bottles and 3 = three positive bottles in the patient’s ﬁrst three-bottle BC set.
(a) (b)
(d)(c)
FIG. 1. (a) 0–30-day and 31–365-day standardized mortality rates (with 95% CIs) for combined groups of C-reactive protein (CRP) level quartile
(1st = 10–64 mg/L; 2nd = 65–143 mg/L; 3rd = 144–240 mg/L; 4th = 241–688 mg/L) and blood culture (BC) index (the number of bacteria-posi-
tive BC bottles (one and two merged) in the initial three-bottle BC set). The model is standardized to the age and comorbidity distribution in
the reference group (1st CRP level quartile with BC indices 1/2). (b) 0–30-day and 31–365-day adjusted mortality rate ratios (with 95% CIs) for
groups, including the reference group, as deﬁned in (a). The model is adjusted for gender, Charlson comorbidity index score, age, specialty,
acquisition of infection, and infection focus.
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stream infections [2,4,16]. Some studies on respiratory tract
infections found no association between the admission CRP
level and mortality [3,5,13,14], whereas others did [6,7]. It is
of note that the baseline CRP level in patients with a respira-
tory focus or S. pneumoniae infection (with substantial over-
lap between the two) was unassociated with short-term
mortality in our study, although prospectively designed stud-
ies are needed to evaluate possible mechanisms.
The main strengths of our study were the unselected
cohort from a geographically well-deﬁned population, the
high number of patients, and the complete long-term
follow-up [21]. The bacteraemia parameters were almost
100% complete, and all bacteraemias were clinically impor-
tant [8].
Our study also had limitations. First, 8.1% of the bactera-
emia patients without baseline CRP measurement were
excluded. However, these excluded patients need extremely
low CRP levels to change the trend of our ﬁndings. Second,
we had no data on previous antibiotic consumption. Early
antibiotic treatment improves the prognosis [22] and lowers
the CRP level [5,14], meaning that such data would probably
corroborate our ﬁndings. Third, we had few clinical data on
bacteraemia severity other than the CRP level. Finally, the
time-span between the start of the infection and the ﬁrst
positive BC varies. Patients with community-acquired bacter-
aemia had higher CRP levels than patients with nosocomial
bacteraemia, probably because the former are infected for a
longer period before receiving medical attention; however,
the consistency in most subgroups indicates the limited
impact of this.
In conclusion, the CRP level at the time of the ﬁrst posi-
tive BC was an independent predictor of 30-day mortality
among an unselected group of adult bacteraemia patients.
The combination with an index of magnitude of bacteraemia
corroborated the prognostic prediction.
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